Melanoma genomes have the highest mutation load of any cancer 1,2 and a predominant C> T nucleotide transition signature attributable to ultraviolet radiation 1 . However, some melanomas lack this signature and have fewer point mutations 3,4 . Melanomas driven by non-ultraviolet radiation are uncommon in cutaneous sites, but dominate those occurring in eyes, mucosal surfaces and acral (hands and feet) sites; the last type account for a much higher proportion of melanomas in Asians 5 than Europeans. Elucidating mutational processes and genomic drivers in all subtypes is key to further progress in melanoma epidemiology, prevention and targeted treatment globally.
and a predominant C> T nucleotide transition signature attributable to ultraviolet radiation 1 . However, some melanomas lack this signature and have fewer point mutations 3, 4 . Melanomas driven by non-ultraviolet radiation are uncommon in cutaneous sites, but dominate those occurring in eyes, mucosal surfaces and acral (hands and feet) sites; the last type account for a much higher proportion of melanomas in Asians 5 than Europeans. Elucidating mutational processes and genomic drivers in all subtypes is key to further progress in melanoma epidemiology, prevention and targeted treatment globally.
The Cancer Genome Atlas (TCGA) study of 333 melanomas 2 excluded acral, mucosal and ocular subtypes and used exome and low-pass whole-genome sequencing (WGS). Examination of mutational process signatures, and of structural changes that drive melanoma, was restricted, and mutations outside the exome were not surveyed. Other sequencing studies have included acral and mucosal melanomas 6, 7 , but have been limited by sample size and/or restriction to exome sequencing.
We present the first large, high-coverage WGS study of melanomas from cutaneous, acral and mucosal sites, revealing distinct mutation processes, profiles and drivers across subtypes, the landscape of non-coding mutations, and paradoxical relationships between telomere maintenance gene mutations and telomere length. Mutational signatures of ultraviolet radiation exposure dominated cutaneous melanomas, while structural variants formed most aberrations in acral and mucosal melanomas. These last subtypes fundamentally differ in pathogenesis and therapeutic targets from cutaneous melanoma.
Study sample and mutation burden
The 183 melanoma samples comprised 75 primary tumours, 93 metastases and 15 cell lines derived from metastases; 35 were acral melanomas (arising from palms, soles or nail beds of the hands or feet), eight were Melanoma of the skin is a common cancer only in Europeans, whereas it arises in internal body surfaces (mucosal sites) and on the hands and feet (acral sites) in people throughout the world. Here we report analysis of whole-genome sequences from cutaneous, acral and mucosal subtypes of melanoma. The heavily mutated landscape of coding and noncoding mutations in cutaneous melanoma resolved novel signatures of mutagenesis attributable to ultraviolet radiation. However, acral and mucosal melanomas were dominated by structural changes and mutation signatures of unknown aetiology, not previously identified in melanoma. The number of genes affected by recurrent mutations disrupting noncoding sequences was similar to that affected by recurrent mutations to coding sequences. Significantly mutated genes included BRAF, CDKN2A, NRAS and TP53 in cutaneous melanoma, BRAF, NRAS and NF1 in acral melanoma and SF3B1 in mucosal melanoma. Mutations affecting the TERT promoter were the most frequent of all; however, neither they nor ATRX mutations, which correlate with alternative telomere lengthening, were associated with greater telomere length. Most melanomas had potentially actionable mutations, most in components of the mitogen-activated protein kinase and phosphoinositol kinase pathways. The whole-genome mutation landscape of melanoma reveals diverse carcinogenic processes across its subtypes, some unrelated to sun exposure, and extends potential involvement of the non-coding genome in its pathogenesis.
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mucosal and the remainder cutaneous (Supplementary Table 1 Table 2 ). Single-nucleotide variant (SNV) and indel frequencies varied by melanoma subtype (t-test, P < 1 × 10 −7 ), with > 18 times more of these mutations in cutaneous (mean 49.17 mutations per megabase, range 0.71-259.69 mutations per megabase) than in acral and mucosal melanomas (mean 2.64 mutations per megabase, range 0.54-15.25 mutations per megabase) (Fig. 1b) . Somatic structural variants were more frequent in acral and mucosal (mean 342.40, range 6-1,148) than in cutaneous melanomas (mean 101, range 3-1,123) (t-test, P < 1 × 10 −6 ) ( Fig. 1c, d ). Greater proportions of the acral and mucosal melanoma genomes showed copy number variation, as in previous exome sequencing 3 ; more regions were amplified (Mann-Whitney U-test, P < 1.46 × 10 −4 ) and more genomes were aneuploid (χ 2 test, P = 0.049) than in cutaneous melanomas (Extended Data Fig. 1 ).
Mutation spectra and ultraviolet radiation
An algorithm using the sequence context of each mutation 1 identified 12 signatures, which varied considerably by melanoma subtype (Fig. 2a-c) . Most melanomas (total n = 139; 136 cutaneous) were dominated by three novel signatures of ultraviolet radiation exposure (signatures 7a, 7b and 7c), recapitulating ultraviolet radiation signature 7 previously identified by exome sequencing 1 (Extended Data Fig. 2 ). The predominantly C> T substitutions at TpC dinucleotides (mutated base underlined) of signature 7a are probably due to repair of 6,4-photoproducts 8 . Signature 7b involves C> T substitutions at CpC and CpC, characteristic of cyclobutane pyrimidine dimers 8 . Signature 7c has high levels of T> C and T> A mutations, potentially caused by indirect DNA damage after ultraviolet radiation. Forty-four tumours, comprising 40 acral or mucosal melanomas and four cutaneous, all from infrequently sun-exposed sites, showed striking differences from the ultra violet radiation-dominant group (Fig. 2) . Six of nine signatures observed in this group have been described in other cancers 9 but never previously in melanoma and are presumably unrelated to ultraviolet radiation exposure. The most frequent were signature 1, the result of endogenous spontaneous deamination of 5-methylcytosine, and signature 5, ubiquitous in cancers of many types and of unknown aetiology 10 (Extended Data Fig. 2 ). Signature 13, attributed to activity of AID/APOBEC cytidine deaminases, occurred in 52 samples (28%) and all melanoma subtypes. Signatures 8, 17 and 18, of unknown aetiology, occurred in all melanoma subtypes at a combined frequency of 7-28%. Signature 6, associated with defective mismatch repair, was seen in the single cutaneous melanoma with a high MSIsensor 11 score.
Structural variants, telomere length
The combined frequency of all structural variants (deletions, duplications, tandem duplications and foldback inversions), was higher in acral and mucosal melanomas than in cutaneous melanomas (t-test,
) ( Fig. 1c and Supplementary Table 3 ). Acral and mucosal melanomas exhibited substantially more clusters of breakpoints, indicating more frequent complex rearrangements such as breakagefusion-bridge (BFB) and chromothripsis (Extended Data Fig. 3a) . We detected complex rearrangements including BFB-like in 18% (n = 32) of tumours, most of which (n = 20, 63%) were acral or mucosal melanomas (Extended Data Figs 4 and 5).
WGS provided the first opportunity to assess effects of mutagenic processes and driver mutation profiles of melanoma on immortalization via telomere length 12,13 (Methods and Extended Data Fig. 6b ). Telomere length varied widely among the 183 samples, ranging from sixfold shorter to tenfold longer than the matched normal for each patient (Extended Data Fig. 6a ). Telomere length was not correlated with melanoma subtype (Extended Data Fig. 6c ), chromothripsis or BFB events (Extended Data Fig. 3 ).
Non-coding mutations
All mutations were annotated for genomic context including regulatory, untranslated and protein coding regions, the first such comprehensive survey in melanoma and one of the first in any cancer. TERT promoter mutations 14,15 were most common (Sanger sequencing), with 115 of 167 (69%) overall and 86% of cutaneous melanomas mutated at one or more of four positions upstream of the initiation codon (Extended Data Fig. 6d ). These mutations created new binding sites for the E26 transformation-specific (ETS) family transcription factor GA-binding protein (GABP) 16 , and were mutually exclusive with the exception of two samples with extremely high mutation burdens. In keeping with previous findings for acral melanoma 17 , these mutations were less prevalent in acral and mucosal melanomas (4 of 38: 11%), accounting for their association with lower structural variant and higher SNV burden (Fisher's exact test, P < 1 × 10
−17
). There was no association between TERT promoter and BRAF mutation (χ 2 test, P > 0.09), in contrast to previous reports 18 . These putatively activating TERT promoter mutations were associated with modestly reduced telomere length (Mann-Whitney U-test, P = 0.0022) (Extended Data Fig. 6e-g ). Telomere elongation in cancer depends either on TERT or a process of alternative lengthening of telomeres 19 , often driven by mutations in ATRX
20
. The mutations in ATRX occur mutually exclusively with TERT promoter mutations in glioblastoma 21 . Ten melanomas (all cutaneous) had predicted loss-offunction mutations in ATRX, including two nonsense mutations, but paradoxically nine of these tumours also carried mutations in the TERT promoter and there was no association between ATRX mutation and telomere length (data not shown). Therefore, mutational activation of TERT does not simply facilitate telomere length extension, and the by subtype (t-test, P < 1 × 10 −7 ): acral and mucosal melanomas (n = 43) carried more than 18-fold fewer mutations than cutaneous melanomas (n = 140). c, Differences in structural variant frequency by subtype (t-test, P < 1 × 10 −6 ): more structural variants in acral and mucosal than cutaneous melanomas. d, Relative abundance of aberrations by body site of the antecedent primary tumour. Highest (red) average SNV counts occurred in sun-exposed areas; highest structural variant counts occurred in sun-shielded body sites of mucosal and acral origin.
relationships between alternative telomere maintenance mechanisms, telomere length and immortalization in melanoma must be complex.
All genes with recurrent mutations in the promoter, 5′ untranslated region (UTR) or 3′ UTR are listed (Supplementary Tables 4-6 ). To detect non-coding elements with an accumulation of functional mutations we used OncodriveFML
22
, which detects signals of positive selection in mutations of coding and non-coding elements. Because of the high mutation rate at active transcription factor binding sites (TFBS) in melanoma 23 , we used a version of OncodriveFML (version 1.1) that permuted mutations locally to assess whether the mutations observed disrupted or created TFBS more often than expected by chance. Promoter regions of nine genes were significantly (q < 0.25) biased towards high-impact mutations: creating new TFBS in BLCAP, KBTBD8, TERT and ZNF778, disrupting them in NSUN6 and RNF185, and with other impacts in RALY, RPL29 and RPS27 (Supplementary Table 4 ). Only in the case of TERT (as previously reported 15 ), RNF185 and RPS27 was an effect of these mutations on gene expression supported. In a further six genes with five or fewer occurrences of a promoter mutation (NUDT10, PNPLA2, CCP110, UAP1, UBAC2 and ZWINT) OncodriveFML predicted creation of novel TFBS; however, too few tumours had such mutations for expression comparisons with wild-type tumours to be informative.
Recurrent mutations in the promoter of NFKBIE were present in 10 of 183 (5%) tumours including 3 of 9 desmoplastic melanomas 24 . The commonest (chr6:44233400) occurred in five melanomas, all cutaneous but lacking a desmoplastic component (Extended Data Fig. 7b ). Mutations at this and one other position (chr6:44233417) have been reported previously, but the other four sites are novel (Extended Data Fig. 7b ) and presumably lie outside the captured exome in the previous study. NFKBIE promoter mutations are thus enriched in desmoplastic melanomas (Fisher's exact test, P < 0.0084), but are also potential drivers of other cutaneous melanomas.
The most frequent 5′ UTR hotspot mutation, detected in 19 of 183 samples, was at the transcription start site of RPS27 (chr1:153963239 C> T) 2,25 and a dinucleotide mutation was detected in one patient (chr1:153963239-153963240 CT> TC). RPS27 also had several recurrent promoter mutations (Extended Data Fig. 7c ), none predicted to cause gain or loss of TFBS. Recurrent mutations also occurred in the 5′ UTR of PES1 (Extended Data Fig. 7d ), RPS14, CHCHD2 and MRPS31 (Supplementary Table 5 ), the last identified as a common hotspot coding mutation by TCGA 2 . The 5′ UTR regions of ERGIC3, PSMD8 and TGS1 were significantly biased towards high functional impacting mutations and were expressed in most tumours; however, none showed expression differences associated with mutation status so their significance as drivers remains uncertain.
TCGA did not report 3′ UTR mutations; we observed recurrent (n ≥ 5) 3′ UTR mutations in 18 genes (Supplementary Table 6 ). Only 11 of these genes were expressed in the tumour cohort and none has been associated with melanoma, except PTPRT which was recently reported to have frequent coding mutations 26 .
Key coding mutations and TCGA genomic subgroups
Two tools were used to identify significantly mutated genes in each of the three melanoma subtypes (MutSigCV and OncodriveFML, q < 0.1; Supplementary Table 7) . Four cutaneous melanoma significantly mutated genes were supported by both methods (BRAF, CDKN2A, NRAS and TP53), and five (ARID2, CWH43, NF1, PTEN and RB1) were supported by one method. SF3B1 was identified as a significantly mutated gene, for the first time in mucosal melanoma, by OncodriveFML. In acral melanoma, OncodriveFML identified BRAF, KIT, MAP2K2, NF1 and NRAS as significantly mutated genes.
Mutation frequencies of previously reported melanoma driver genes 2,3,26-30 varied considerably between melanoma subtypes. For example, no acral or mucosal melanomas had mutations in TP53, PTEN, DDX3X, RASA2, PPP6C, RAC1 or RB1, indicating that the molecular pathways driving these melanoma subtypes differ markedly from those driving cutaneous melanoma. In line with previous studies 31 , KIT mutations occurred more frequently in acral (3 of 35) and mucosal melanomas (2 of 8) than in cutaneous melanomas (6 of 140) (χ 2 test, P < 0.044). The distribution of mutations in selected melanoma genes (Supplementary Table 8 ) is shown in Fig. 3 . Structural variants and copy number variation contributed heavily to the overall mutation frequency of some melanoma driver genes, especially NF1, TP53, PTEN and KIT (Extended Data Fig. 1b, c and Fig. 3) . BRAF hotspot mutations were usually amplified, and these structural variants tended to involve MET, adjacent on chromosome 7. Similarly, KIT and novel ultraviolet radiation signatures, whereas melanomas with low mutation burden (acral or mucosal, n = 43) were dominated by signature 1 (associated with age), signature 5 (aetiology unknown and ubiquitous in diverse cancers) and signature 8 (seen in medulloblastoma and breast cancer).
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PDGFRA, co-located within 0.35 megabases on chromosome 4, were frequently co-amplified. MITF amplifications were present in 10% of samples, and in all three melanoma subtypes. Many acral and mucosal melanomas had structural variants and high-level amplifications on the long arm of chromosome 11, often targeting CCND1 (Extended Data Fig. 3c ).
We analysed the genomic subgroups of melanoma proposed by TCGA: BRAF mutated, RAS mutated, NF1 mutated or triple wild type 2 ( Fig. 3a and Extended Data Figs 8 and 9). NF1 aberrations occurred in 32 of 183 (17%) samples, and in 14 they were bi-allelic; 23 had point mutations/small indels only (15 nonsense, 4 missense, 3 splice site and 1 frameshift). Structural variants contributed heavily (Fig. 3b) to mutation burden in NF1, so previous studies in which structural variants were not assessed will have underestimated the NF1-mutated group and overestimated the proportion of triple wild-type melanomas. NF1 mutation was found to co-occur with RASA2 mutation (Fisher's exact test, P < 0.003), as recently described 29, 32 . Most mucosal and acral (n = 22 of 43, 51%) melanomas, but only 15 of 140 (11%) cutaneous melanomas lacked BRAF, NRAS or NF1 mutations; mutations in other cancer driver genes were frequent in this triple wild-type group, including loss-of-function mutations in CDKN2A, TP53 and ARID2, and activating hotspot mutations in GNAQ and SF3B1. Notably, one GNAQ and three SF3B1 mutations, commonly mutated in uveal 33,34 but not cutaneous melanoma 2 , were found exclusively in four of six triple wild-type mucosal melanomas, marking an unappreciated set of driver genes and pathways shared by mucosal and uveal melanomas. Seven triple wild-type melanomas carried mutations in KIT, five of which had high-level amplifications. Triple wild-type melanomas had more focal amplifications of KIT, CCND1, MDM2 and KRAS than did non-triple wild-type melanomas (Fisher's exact test, P < 5.4 × 10 , 0.018 and 0.003, respectively). Table 3 ) and known melanoma tumour suppressor genes: NF1 (n = 3), PARK2 (n = 2), TP53, PTEN and PPP6C. RAF1 gene fusions, shown to increase MAP-kinase kinase (MEK) phosphorylation compared with wild-type RAF1, were observed in one triple wild-type and one NF1-mutated tumour 39 . The same RAF1 exons were retained in both fusions, albeit fused to different genes (CDH3 and GOLGA4) (Extended Data Fig. 9 ). In RNA sequencing of 44 samples, 17 of 136 potential fusion genes were expressed (Supplementary Table 3 ).
Gene fusions
Fusions involved several kinase genes (Supplementary Table 3 ), the most frequently affected being PAK1 (n = 5 samples: four acral melanomas, two of which were triple wild-type, and one cutaneous carrying a BRAF V600E mutation). These PAK1 fusions are unlikely to be activating: the kinase domain was retained in four of five samples, in each case there was a different gene fusion partner (AQP11, FCHSD2, TENM4, OR9Q1) and two to four additional breakpoints within the PAK1 gene. The next most frequently fused kinase gene was DGKB, with two fusions in acral triple wild-type melanomas and one in a cutaneous BRAF V600E mutated sample, each with multiple breakpoints within the DGKB gene with probable loss of function.
Signalling activation and clinical implications
All subtypes were dominated by mutations to the mitogen-activated protein kinase (MAPK) and phosphoinositol 3-kinase (PI3K) pathways, and receptor tyrosine kinase (RTK) (Supplementary Table 9 and Fig. 4b ). The MAPK signalling pathway was enriched 1.34-fold (Fisher's exact test, q < 1 × 10
) and bore mutations in 179 of 183 (98%) samples. Samples that harboured a mutated gene in both the MAPK and PI3K pathways had the highest proportion of phosphorylated (p-) ERK-positive tumour nuclei, whereas samples that were wild type for all genes in the PI3K and MAPK pathways had the lowest proportion ( Fig. 4c, d ). The highest p-AKT activation levels were seen in cases with only PI3K altered, whereas MAPK only and MAPK/PI3K wild-type cases had the lowest (differences not significant, one-way analysis of variance and post hoc Tukey's test).
Nearly all cutaneous (138 of 140, 99%) and most non-cutaneous (39 of 43, 91%) melanomas harboured a SNV/indel or structural variant breakpoint in one or more genes that can confer sensitivity to an agent that is approved by the US Food and Drug Administration or currently in a cancer clinical trial (Extended Data Fig. 10 ). The frequency of mutation and copy number variation of some potentially actionable genes (CCND1, CCND2, KIT, KRAS, MDM2 and PIP5K1A) was significantly higher in non-cutaneous than cutaneous melanomas (twoproportion z-test, all P < 0.05). 
This is the largest WGS analysis of melanoma so far and the largest to compare cutaneous, acral and mucosal subtypes. Acral and mucosal melanomas showed a markedly different genomic landscape from cutaneous melanoma, with a far lower mutation burden dominated by large-scale structural variants. Novel mutagen signatures in cutaneous melanomas probably reflect uncharacterized mechanisms of ultraviolet radiation damage. The principal mutation mechanisms driving mucosal and most acral melanomas were, in contrast, not attributable to ultraviolet radiation and imply novel carcinogenic exposures that are shared with cancers other than skin cancer. Notably, some mucosal melanomas exhibited significantly mutated genes (GNAQ, SF3B1) previously characteristic of uveal melanoma. In further contrast to cutaneous melanomas, acral and mucosal melanomas were infrequently driven by TP53, PTEN or RB1 pathway lesions, and exhibited a variety of 'triple wild-type' mechanisms such as KIT mutations and focal amplifications of KIT, CCND1, MDM2 and KRAS. Novel recurrently fused genes were also identified (PAK1, DGKB). Most cutaneous and non-cutaneous melanomas exhibited mutations in genes for which targeted therapies exist or are being evaluated in clinical trials. 
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Non-coding mutations were surveyed for the first time at scale in melanoma, and their significance assessed taking into account the high mutation load at TFBS in melanoma 23 . The number of genes affected by recurrent non-coding mutations predicted to have a strong functional impact was equivalent to the number of genes affected by recurrent significant coding mutations. Eight genes in addition to TERT showed potential driver promoter mutations (BLCAP, KBTBD8, NSUN6, RALY, RNF185, RPL29, RPS27 and ZNF778). Recurrent, probably functional 5′ UTR mutations were observed in CHCHD2, PES1 and RPS14, as well as in genes previously reported as mutated (RPS27, MRPS31). Recurrent 3′ UTR mutations were common, and of uncertain significance, although PTPRT also carries frequent coding mutations 28 . Finally, we show the highly prevalent TERT promoter mutations in melanoma must confer selective advantage via dysregulation of telomere protection, whether by telomerase or the alternative lengthening of telomere mechanism, since they result in reduced, not increased, telomere length.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. Supplementary Information is available in the online version of the paper.

METHODS
No statistical methods were used to predetermine sample size. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. Human melanoma samples. The fresh-frozen tissue and blood samples analysed in the current study were obtained from Australian melanoma biospecimen banks, including the Melanoma Institute Australia (n = 160), Australasian Biospecimen Network-Oncology Cell Line Bank QIMR-Berghofer Institute of Medical Research (n = 15; all lines authenticated by DNA profiling and tested for mycoplasma contamination), Ludwig Institute for Cancer Research (n = 4) and Peter MacCallum Cancer Centre/Victorian (n = 4) biospecimen banks. All tissues and bloods form part of prospective collection of fresh-frozen samples accrued with written informed patient consent and institutional review board approval. Fresh surgical specimens were macro-dissected and tumour tissues were procured (with as little contaminating normal tissue as possible) and snap frozen in liquid nitrogen within 1 h of surgery. All samples were pathologically assessed before inclusion into the study, with samples requiring greater than 80% tumour content and less than 30% necrosis to be included. All samples were independently reviewed by melanoma pathologists (R.A.S., R.E.V.) to confirm the presence of melanoma and qualification of the above criteria. Samples requiring tumour enrichment underwent macrodissection or frozen tissue coring (Cryoxtract, Woburn, Massachusetts, USA) using a marked haematoxylin and eosin slide as a reference. The histopathology of all mucosal and acral samples was reviewed by R.A.S. to confirm the diagnosis. Acral melanomas were classified as occurring within acral skin of the palm of the hand, sole of the foot and under nail beds. The lack of hair follicles, thickened stratum corneum and clinical site was confirmed in all cases. Mucosal melanomas were defined as occurring in the mucosal membranes lining oral, respiratory, gastrointestinal and urogenital tracts. The haematoxylin and eosin slides of the primary melanomas were reviewed for all mucosal and acral samples, and any tumour that arose in the junction of the acral/mucosal and cutaneous skin was excluded. Occult/unknown primary melanomas were considered cutaneous, since their genome landscape is indistinguishable from that of melanomas arising in the skin 40 . DNA extractions. Tumour DNA was extracted using DNeasy Blood and Tissue Kits (69506, Qiagen), according to the manufacturer's instructions. Blood DNA was extracted from whole blood using Flexigene DNA Kits (51206, Qiagen). All samples were quantified using the NanoDrop (ND1000, Thermoscientific) and Qubit dsDNA HS Assay (Q32851, Life Technologies), and DNA size and quality were tested using gel electrophoresis. Samples with a concentration of less than 50 ng μ l −1 , or absence of a high molecular mass band in electrophoresis gels, were excluded from further analyses. WGS. WGS was performed on Illumina Hiseq 2000 instruments (Illumina, San Diego, California, USA) at three Australian sequencing facilities (Australian Genomic Research Facility, Ramaciotti Centre for Genomics, John Curtin School of Medical Research) and Macrogen (Geumcheon-gu, Seoul, South Korea). All facilities performed library construction using TruSeq DNA Sample Preparation kits (Illumina) according to the manufacturer's instructions. The subsequent 100 base pair (bp) pair-end libraries were sequenced using Truseq SBS V3-HS kits to average depth 85× (range 43-219× ) in the tumour sample and 64× (range 30-214× ) in the matched normal. WGS processing and quality control. Sequence data were aligned to the GRCh37 assembly using multi-threaded BWA 0.6.2-mt, resulting in sorted lane level files in sequence alignment/mapping format which were compressed and converted to binary file (BAM) created by samtools 0.1.19. Sample-level merged BAMs, one each for matched germline and tumour samples, were produced by in-house tools and duplicate reads marked with Picard MarkDuplicates 1.97 (http://picard. sourceforge.net). Quality assessment and coverage estimation was performed by qProfiler and qCoverage (http://sourceforge.net/projects/adamajava). To test for the presence of sample or data swaps, all sequence data were assessed by qSignature for concordance at approximately 1.4 million polymorphic genomic positions including the genotyping array data where available. Somatic mutation analysis. Somatic mutations and germline variants were detected using a dual calling strategy using qSNP 41 and GATK
42
, and indels of 1-50 bp in length were called with Pindel 43 . All mutations were submitted to the International Cancer Genome Consortium 44 Data Coordination Centre. Mutations were annotated with gene consequence using Ensembl gene annotation with SnpEff. Somatic genes that were significantly mutated were identified using two approaches: MutSigCV and OncodriveFML 1.1 (ref. 22) using a threshold of q < 0.1. Significant non-coding elements were detected using OncodriveFML 1.1 (ref. 22) .
Somatic copy number and ploidy were determined using the TITAN tool 45 . Structural variants were identified using the qSV tool and chromosomes containing highly significant non-random distributions of breakpoints were identified as previously described 46 . Chromosomes identified to have clustering of breakpoints were inspected against criteria for chromothripsis 47 and the BFB cumulative rearrangement model 48 . Chromosomes with high numbers of translocations were identified with a minimum threshold of ten translocation breakpoints per chromosome following manual review.
Mutational signatures were predicted in each sample using a published framework 1 . Essentially, the substitution mutations across the whole genome in all cases were analysed in context of the flanking nucleotides (96 possible trinucleotide combinations). Identified signatures were compared with other validated signatures and the frequency of each signature per megabase was determined. Recurrent non-coding mutations. Statistical significance of recurrent non-coding mutations was estimated using a permutation test. A null distribution of recurrence was estimated by randomly shuffling all mutations within each sample and recording the number of recurrent mutations within the regions of interest. To take into account not only the varying mutation burden but also the different mutation signatures, we restricted the random shuffling such that the mutation in the middle of a trinucleotide, ABC, was only shuffled to the same trinucleotide. Functional impact bias of mutations in promoters, 3′ UTRs and 5′ UTRs. Promoters and UTRs likely to play a role in tumorigenesis were identified with OncodriveFML 22 , a framework able to detect signals of positive selection in both the coding and the non-coding regions of the genome by measuring the bias towards the accumulation of functional mutations. The functional impact of mutations in gene promoters was assessed using the CADD (Combined Annotation Dependent Depletion) 49 , TFBS creation and TFBS disruption scores. The CADD scores measure the deleteriousness of mutations, and are calculated by integrating multiple annotations into a single metric by contrasting variants that survived natural selection with simulated mutations. The scores for TFBS creation (motif gain) and disruption (motif break) were computed by following the steps described in ref. 50 . The score value indicates the difference between position weight matrix matching scores of the germline and mutant alleles. The 5′ UTRs were analysed using the TFBS disruption scores while 3′ UTRs were analysed using the CADD scores. The statistical significance of promoters and UTRs was derived by comparing the average functional impact score of the mutations in the element with the functional impact scores obtained by permuting 100,000-fold the observed mutations, maintaining their trinucleotide context. In addition, since the rate of somatic mutations in melanoma is highly increased at active TFBS 23 , OncodriveFML was adapted (version 1.1) to perform a strictly local permutation in windows of 51 bp (25 nucleotides at each side of the mutation). This variation in the background model of OncodriveFML allowed us to better estimate whether the mutations observed in tumours disrupted or created TFBS more than expected by chance. The statistical significance of promoters and UTRs mutated in at least two samples was adjusted with the Benjamini-Hochberg correction for multiple testing.
We also used miRanda version 3.3a to predict whether the recurrent 3′ UTR mutations alter (disrupt or create) microRNA (miRNA) binding sites. The 50-base sequence surrounding each 3′ UTR was used as input to miRanda. miRNAs that were predicted to hit either the wild-type or mutant sequence (but not both) were considered potential targets and further filtered as follows. We required a hit to perfectly align against the seed region of the miRNA (nucleotides 2-8), that the mutation lay within the seed and that the predicted binding energy was higher (lower Δ G) in the non-hit than in the hit. Telomere length estimation. To estimate telomere length, we counted telomere motifs in the whole gene data using the quantitative-PCR-validated qMotif tool (https://sourceforge.net/p/adamajava/wiki/qMotif) implemented in JAVA using the Picard library (version 1.110). qMotif is driven by a single plain-text configuration file in the 'Windows INI-file' style and the input is a WGS BAM file that has been duplicate-marked and coordinate-sorted. Essentially, qMotif uses a two-stage matching system where the first stage is a quick-but-strict string match and the second stage is a slower but more flexible regular expression match; only reads that pass stage 1 go on to the much slower match in stage 2. For telomere quantification, a string representing three concurrent repeats of the canonical telomere motif (TTAGGGTTAGGGTTAGGG) was used as the stage 1 match, and a simple pattern match for stage 2 which captured any read with two or more concurrent occurrences of the telomeric repeat with variation allowed in the first three bases. The relative tumour telomere length was then estimated by comparing the tumour read counts with the matched normal sample. Telomere length was validated by quantitative PCR 51 . Sanger sequencing of TERT promoter. Direct PCR amplification and Sanger sequencing were performed using the primers hTERT_F ACGAACGTGG CCAGCGGCAG and hTERT_R CTGGCGTCCCTGCACCCTGG, which amplify a 474 bp region of the TERT promoter 52 . PCR was done in a 13 μ l volume containing 1 μ l of 20 ng μ l −1 gDNA, 1.25 μ l of 10× MgCl 2 , 2.5 μ l betaine, 1.25 μ l deoxynucleotides (2.5 mM), 1 μ l of 10 μ M primers and 0.25 μ l of PFU Turbo (600250, Agilent). PCR reactions were performed under the following conditions: 95 °C for ARTICLE RESEARCH 5 min, followed by four cycles of 95 °C for 30 s, annealing at 66 °C for 1 min and polymerization at 72 °C for 1 min. This was followed by 4 more cycles with a lowered annealing temperature of 64 °C for 1 min, followed by 28 cycles with annealing temperatures of 62 °C. Subsequent PCR products were sequenced on an AbiPrism 3130xl Genetic Analyzer (Applied Biosystems) and data analysed using Sequence Scanner Software 2 (Applied Biosystems) with reference to the sequences from the NCBI gene database, TERT (chr5:1295071-1295521). Ultra-deep custom amplicon sequencing of non-coding mutations. Illumina TruSeq Custom Amplicon V1.5 was used to validate 20 recurrent non-coding point mutations in the promoter (n = 11), 3′ UTR (n = 3) and 5′ UTR (n = 6) regions of genes with frequent non-coding mutations in 164 of the 183 samples. Illumina DesignStudio (Illumina, San Diego, California, USA) was used to design 250 bp sequences of the target regions. Sequencing libraries were prepared using the TruSeq Custom Amplicon Library Preparation Guide and the TruSeq Custom Amplicon Index Kit, and sequenced on a MiSeq Illumina sequencer V2 (Illumina). Sequences were aligned to the reference genome (GRCh37/hg19) using BWA 0.6.2-mt. A pileup approach was used to determine the base count at each position of interest. A mutation was considered verified if the mutant allele frequency was > 10%. Exome sequencing. Exome capture was performed on 1 μ g of DNA extracted from tumour and normal blood using an Illumina TruSeq Exome Library Prep Kit. Libraries were sequenced (paired-end sequencing) on an Illumina HiSeq2000 platform with a minimum coverage of 61× (normal) and 59× (tumour). Exome sequence data were produced for 53 patients in the cohort and used to validate coding mutations detected by WGS. RNA extraction and sequencing. Total RNA was extracted from fresh-frozen tissue using a mirVana miRNA Isolation Kit (Applied Biosystems, AM1560). RNA quality and presence of a small RNA fraction were measured using the Agilent 2100 RNA 6000 Nano and small RNA kits. RNA sequencing was performed using 1 μ g of total RNA, which was converted into messenger RNA libraries using an Illumina mRNA TruSeq kit. RNA sequencing was performed using 2 × 75 bp paired-end reads on an Illumina Hiseq2000. Small RNA sequencing was performed using 1 μ g of total RNA, which was converted into a small RNA libraries, size selection range 145-160 bp (RNA of 18-33 nucleotides) using Illumina's TruSeq Small RNA Library Preparation Kit and sequenced on an Illumina Hiseq2000 using 50 bp single-read sequencing with 1% control spiked in.
RNA sequence reads were aligned to transcripts corresponding to ensemble 70 annotations using RSEM 53 . RSEM data were normalized using TMM (weighted trimmed mean of M-values) as implemented in the R package 'edgeR' . For downstream analyses, normalized RSEM data were converted to counts per million. Genes with at least 5 counts per million in at least two samples were considered expressed. Body site distribution of SNV/indel and structural variants. Total numbers of SNV/indel and structural variants were compared according to primary melanoma body site, categorized into abdomen, acral hand, acral foot, back, lower arm, lower leg, mucosal, neck, shoulder, thorax, upper arm, upper leg, and face and scalp. Any samples with an unknown primary site or occult classification were excluded from analysis. Heat maps were produced in Spotfire-Tibco (version 6.0, http://spotfire. tibco.com) on the basis of the combined total number of SNV and indels, or by structural variants. A two-colour heat map (red high, blue low) was produced and colours were overlaid onto an adapted SVG human body diagram that was created using Adobe Illustrator CS6. Clinically actionable gene mutations. The frequency of clinically actionable mutations was assessed by annotating genomic variants using the IntOGen Cancer Drivers Actionability database (2014), which identifies mutations that may confer sensitivity to therapeutic agents 54 . The database was used to assign an activating or loss-of-function role to mutated genes. Loss of heterozygosity, silent mutations, deletions to activating genes or amplifications to loss-of-function genes were not included in the analysis. Additionally, visual inspection using the Integrative Genome Viewer (IGV, Broad) was used to identify only high-confidence structural rearrangement breakpoints with clustered supporting reads with both discordant read pair and soft clipping evidence. Structural variants with a high incidence of random non-clustered background signal surrounding the breakpoints along with low numbers of supporting non-duplicate reads were excluded from analysis for this figure (Extended Data Fig. 10 ). The proportion of tumours with a mutation to a particular actionable gene was calculated and classified on the basis of mutation type into (1) SNV/indel, (2) SNV/indel and structural variant, (3) structural variant or (4) copy number variation only.
Commonly mutated genes and pathways. A hand-curated list of commonly mutated tumour suppressor genes and oncogenes was created and analysed for the frequency of mutation (Fig. 4a ). Mutations were defined as SNV/indel, structural variant, copy number amplifications and copy number deletions. Loss of heterozygosity, silent mutations, RNA mutations, deletions to oncogenes or amplifications to tumour suppressor genes were not included in the figure. Structural variant breakpoints were subjected to manual inspection using the Integrative Genome Viewer (IGV, Broad) and only events confirmed as somatic and predicted to alter transcription processing were considered further. We then overlaid the alterations from Fig. 4a onto pathways defined by Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) gene sets from MSigDB version 5.0. A pathway was considered altered in a given sample if at least one gene in the pathway contained an SNV/indel or structural variant. The pathways were then stratified according to cutaneous or non-cutaneous subtypes. A mutation file with sample identities and their mutated pathways was entered for analysis into the OncoPrinter tool (http://cbioportal.org). Multiplex-immunofluorescent staining. MAPK and PI3K pathway status was also assessed by multiplex-immunofluorescent staining for phosphorylated ERK and AKT (106/183). All immunohistochemical staining was performed on a Dako Autostainer Plus (Dako, Glostrup, Denmark) using a Dako Envision Flex detection kit (K8000, Dako) and OPAL 7-colour IHC Kit for visualization (NEL797B001KT, PerkinElmer). Consecutive staining rounds included p-AKT (1:100, NCL-L-AktPhos, Leica), p-ERK (1:1,600, CS4370, Cell Signalling) and SOX10 (1:800, ACI 3099A, Biocare). Multispectral quantitative image analysis was performed on a Vectra 3 slide scanner (PerkinElmer, USA). The captured multispectral images were analysed using the quantitative InForm image analysis software (PerkinElmer, USA). Data deposition. All somatic variants for this study have been deposited in the International Cancer Genome Consortium Data Coordination Centre and are publicly available at https://dcc.icgc.org. The BAM files have been deposited in the European Genome-phenome Archive (https://www.ebi.ac.uk/ega/) with accession number EGAS00001001552. Code availability. Tools used in this publication that were developed in-house are available from the SourceForge public code repository under the AdamaJava project (http://sourceforge.net/projects/adamajava/). Data availability. Source data are provided or are available from the corresponding author upon reasonable request. Twelve mutation signatures in melanoma were identified taking into account the sequence context immediately before and after the mutation. Each signature is displayed showing the probability for each of the 96 mutation types. a, Three novel signatures, associated with ultraviolet radiation, were identified. These signatures perfectly recapitulate the ultraviolet radiation mutation signature previously extracted from exome sequencing data. Signature 7a is predominately C> T transitions occurring at TpC dinucleotides and, on the basis of similarity with the sequence context, it is most likely owing to the formation of 6,4-photoproducts. Signature 7b is described by C> T transitions at CpC dinucleotides. This sequence context is characteristic for the formation of cyclobutane pyrimidine dimers due to ultraviolet radiation exposure. Signature 7c has a high proportion of C> T substitutions, and high levels of T> C and T> A mutations, demonstrating the ability of ultraviolet radiation to generate both transitions and transversions. The underlying processes damaging DNA and resulting in signature 7c are currently unknown but they could potentially be due to indirect DNA damage. b, Of the nine non-ultraviolet radiation associated signatures, three (signatures 1, 5 and 17) have previously been observed in melanoma and six have been seen in other cancer types but not previously noted in melanoma. Signature 1 is the result of an endogenous mutational process initiated by spontaneous deamination of 5-methylcytosine and is associated with age of the patient. Signature 5 (aetiology unknown) was the dominant signature in tumours with no ultraviolet radiation signature; it is, together with signature 1, the most common signature, observed in diverse cancer types. Signature 17 (aetiology unknown) has been seen in melanoma previously and was here observed in 52 tumours (exclusively cutaneous and acrals). Signature 8 was one of the dominant signatures in tumours with no ultraviolet radiation signature (together with signatures 5 and 1); it has previously been observed in breast cancer and medulloblastoma and was evident in 39 melanomas. Signatures 2 and 13 have been attributed to activity of the AID/APOBEC family of cytidine deaminases and are often observed in the same samples; here, most non-ultraviolet samples showed both signatures, but the highest level of signature 2 was observed in a cluster of four samples in which signatures 2, 7a and 7c were observed. Signature 6 is associated with defective DNA mismatch repair and typically found in microsatellite-unstable tumours; it was observed in one melanoma in this cohort. Signature 18 has been observed frequently in neuroblastoma; it was identified in 13 melanomas. Signature R2 reflects a sequencing artefact. The observed pattern of breakpoint clusters and copy number events was used to classify tumours as BFB-associated, complex, highly rearranged or no clusters of events. TERT promoter mutations are also shown. c, Patterns of structural variants and copy number in all acral melanomas that contained a cluster of structural variants on chromosome 11. Graphs show the most frequent translocations and other structural variants (copy number in red, gain; in green, loss). G  T  T  C  C  T  G  A  T  C  G  G  G  A  A  G  G  C  C  G  C  G  T  A  T  C  C  G  T  T  A  C  T  G  C  G  T  T  G  A  G  G  C  G  G  G 
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